PharMida

PharMida is a biotechnology company focused on the discovery and development of small molecule therapeutics targeting the Macrophage Migration Inhibitory Factor (MIF) pathway. Founded by former scientists from the National Institutes of Health (NIH), the company leverages deep expertise in MIF biology to address unmet needs in oncology and inflammatory diseases. Its lead research programs involve potent and selective inhibitors of MIF's tautomerase activity, which plays a critical role in promoting tumor growth and chronic inflammation. By disrupting these pathways, PharMida aims to modulate the immune microenvironment and provide novel treatment options for patients with solid tumors and autoimmune disorders. The company has historically been supported by federal grants and collaborations with academic institutions.